GlassScriptPhysician profile
Patricia G Wheeler
NPI 1508975376
$640.70
in general payments reported to CMS, 2019-2025
11 companies · $23.46 in 2025
The $23.46 reported for 2025 was less than what a typical Clinical Genetics (M.D.) provider received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $300 · 2023: $101 · 2024: $216 · 2025: $23.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $145.21 | 2022-2024 | Voxzogo 1.2mg |
| Genentech USA, INC. | $144.44 | 2023-2024 | Evrysdi |
| Ptc Therapeutics, INC. | $124.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.65 | 2023-2024 | Vpriv |
| Acadia Pharmaceuticals INC | $40.13 | 2023 | Daybue |
| Glaukos Corporation | $33.60 | 2024 | Idose |
| Travere Therapeutics, INC. | $26.05 | 2023 | Cholbam |
| Abbvie INC. | $23.90 | 2022 | |
| Biogen, INC. | $23.46 | 2025 | Skyclarys |
| Eusa Pharma (US) LLC | $19.13 | 2022 | |
| Recordati_rare_diseases_inc. | $19.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.